Given that the iKRASsig signature used for our drug repurposing approach was upregulated in both pancreatic and colorectal cancers25, investigating the effect of MEKi- and KRASi-based combinatorial approaches involving mtPKCi’s across KRAS-driven tumors may unveil unanticipated interventional opportunities for this type of tumors and, thus, expand our current armamentarium for these deadly cancers. This evidence concerns the gene KRAS and cancer.